Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Palopegteriparatide
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
VISEN Pharma PaTHway China Trial Achieves Endpoints in Hypoparathyroidism
Details : Yorvipath (palopegteriparatide) is a prodrug of PTH 1-34, which is designed to provide normal parathyroid hormone levels. It is approved for the treatment of adults with chronic hypoparathyroidism.
Brand Name : Yorvipath
Molecule Type : Peptide
Upfront Cash : Not Applicable
August 12, 2024
Lead Product(s) : Palopegteriparatide
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lonapegsomatropin
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
VISEN's Biologics License Application for Lonapegsomatropin Accepted in China
Details : Skytrofa (lonapegsomatropin) delivers unmodified somatropin for treating children with growth failure due to insufficient growth hormone, with its BLA accepted in China.
Brand Name : Skytrofa
Molecule Type : Large molecule
Upfront Cash : Not Applicable
March 07, 2024
Lead Product(s) : Lonapegsomatropin
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : C-type Natriuretic Peptide Prodrug
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective in Accomplish China Phase 2 Trial
Details : TransCon CNP (c-type natriuretic peptide prodrug) is a FGFR 3 inhibitor. It is being evaluated for the treatment of children with achondroplasia (ACH) aged 2 to 10 years.
Brand Name : TransCon CNP
Molecule Type : Peptide
Upfront Cash : Not Applicable
November 16, 2023
Lead Product(s) : C-type Natriuretic Peptide Prodrug
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Palopegteriparatide
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TransCon PTH (palopegteriparatide) is designed to restore physiologic levels and activity of parathyroid hormone (PTH) throughout 24 hours per day, thereby addressing full aspects of the HP disease, including normalizing serum and urinary calcium and ser...
Brand Name : TransCon PTH
Molecule Type : Peptide
Upfront Cash : Not Applicable
January 06, 2023
Lead Product(s) : Palopegteriparatide
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lonapegsomatropin
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Ascendis Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
VISEN Discloses 52-week Clinical Results for Its China Phase 3 Trial of Lonapegsomatropin
Details : ACP-011 (lonapegsomatropin), a long-acting prodrug of unmodified somatropin is being investigated as a once-weekly injection in children with growth hormone deficiency (GHD) in China.
Brand Name : ACP-011
Molecule Type : Peptide
Upfront Cash : Not Applicable
November 17, 2022
Lead Product(s) : Lonapegsomatropin
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Ascendis Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lonapegsomatropin
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Top-line results of TransCon hGH, from the trial indicate that lonapegsomatropin was well-tolerated and with comparable safety to daily growth hormone. The safety profile of lonapegsomatropin in Chinese children with GHD was consistent.
Brand Name : TransCon hGH
Molecule Type : Peptide
Upfront Cash : Not Applicable
May 23, 2022
Lead Product(s) : Lonapegsomatropin
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : TransCon PTH
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The primary endpoints of the study include evaluating the safety, tolerability and efficacy of once-daily subcutaneous injection of TransCon™ PTH in adults with HP.
Brand Name : TransCon PTH
Molecule Type : Peptide
Upfront Cash : Not Applicable
June 02, 2021
Lead Product(s) : TransCon PTH
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : TransCon PTH
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Ascendis Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The multicenter, randomized, open-label and parallel control study aims to demonstrate noninferiority in annualized height velocity following weekly injections of TransCon hGH compared to once daily dosing of hGH after 52 weeks of treatment in prepuberta...
Brand Name : TransCon PTH
Molecule Type : Peptide
Upfront Cash : Not Applicable
March 30, 2021
Lead Product(s) : TransCon PTH
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Ascendis Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Lonapegsomatropin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Sequoia China
Deal Size : $150.0 million
Deal Type : Series B Financing
VISEN Pharmaceuticals Closes $150 Million Series B Financing
Details : Proceeds of the Series B financing will be used to accelerate the clinical development of the potential best-in-class portfolio drug candidates and to build a strong foundation for commercialization.
Brand Name : TransCon hGH
Molecule Type : Peptide
Upfront Cash : Undisclosed
January 09, 2021
Lead Product(s) : Lonapegsomatropin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Sequoia China
Deal Size : $150.0 million
Deal Type : Series B Financing
Lead Product(s) : Natriuretic Peptide, C-Type
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : China Center for Drug Evaluation (CDE) of National Medical Products Administration (NMPA) has approved VISEN's IND application to conduct a phase 2 clinical trial of TransCon TM C-Type Natriuretic Peptide (CNP) for patients with achondroplasia (ACH).
Brand Name : TransCon CNP
Molecule Type : Peptide
Upfront Cash : Not Applicable
January 07, 2021
Lead Product(s) : Natriuretic Peptide, C-Type
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?